|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00353808 |
The purpose of this study is to assess the long-term safety and tolerability of [S,S]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.
Condition | Intervention | Phase |
Pain |
Drug: [S,S]-Reboxetine |
Phase II |
MedlinePlus related topics: | Shingles |
Drug Information available for: | Reboxetine Reboxetine mesylate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN). |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 57 Study Locations |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Study ID Numbers: | A6061029 |
First Received: | July 17, 2006 |
Last Updated: | July 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00353808 |
Health Authority: | United States: Food and Drug Administration |
|
|
|